RAPP Stock Forecast 2025-2026
Distance to RAPP Price Targets
RAPP Price Momentum
🤔 Considering Rapport Therapeutics (RAPP)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest RAPP Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, RAPP has a bullish consensus with a median price target of $35.00 (ranging from $35.00 to $42.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $10.51, the median forecast implies a 233.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Justin Walsh at Jones Trading, projecting a 299.6% upside. Conversely, the most conservative target is provided by Andrew Tsai at Jefferies, suggesting a 233.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RAPP Analyst Ratings
RAPP Price Target Range
Latest RAPP Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RAPP.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Oct 18, 2024 | Jones Trading | Justin Walsh | Buy | Initiates | $42.00 |
| Jul 2, 2024 | TD Cowen | Joseph Thome | Buy | Initiates | $0.00 |
| Jul 2, 2024 | Jefferies | Andrew Tsai | Buy | Initiates | $35.00 |
| Jul 2, 2024 | Stifel | Paul Matteis | Buy | Initiates | $35.00 |
Rapport Therapeutics Inc. (RAPP) Competitors
The following stocks are similar to Rapport Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Rapport Therapeutics Inc. (RAPP) Financial Data
Rapport Therapeutics Inc. has a market capitalization of $409.12M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -35.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Rapport Therapeutics Inc. (RAPP) Business Model
About Rapport Therapeutics Inc.
Develops neurological medicines and therapies.
Rapport Therapeutics generates revenue by developing innovative therapies aimed at treating neurological disorders. The company utilizes a unique platform that integrates neuroscience, medicinal chemistry, and genetics, allowing it to identify and create targeted drug candidates. By addressing unmet medical needs in areas like epilepsy and neuropathic pain, it positions itself to capture significant market opportunities.
Rapport Therapeutics is focused on advancing treatment options for challenging neurological conditions, which may lead to improved patient outcomes and quality of life. Its holistic approach seeks to ensure both efficacy and safety in drug development, making it a key player in the biotech sector amid ongoing challenges in traditional treatment methods.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
69
CEO
Mr. Abraham N. Ceesay M.B.A.
Country
United States
IPO Year
N/A
Website
www.rapportrx.comRapport Therapeutics Inc. (RAPP) Latest News & Analysis
Rapport Therapeutics reported positive PET trial results for RAP-219, with Phase 2a epilepsy trial results expected Q3 2025. They ended 2024 with $305.3M in cash, funding operations through 2026.
Positive trial results for RAP-219 signal potential breakthroughs in epilepsy and CNS disorders, which could drive stock value. Strong cash position ensures funding for upcoming trials, enhancing growth prospects.
Mise à disposition des éléments préparatoires à l'AG du 28/03/2025 - Rapport Financier Annuel 2024
3 days agoPreparatory information for the Ordinary and Extraordinary General Meetings scheduled for March 28, 2025, has been released.
The announcement of upcoming shareholder meetings provides insight into corporate governance and potential changes that could impact company strategy and stock performance.
Les Assemblées Générales Ordinaires et Extraordinaires de 2025 se tiendront le 28 mars 2025. Des informations préparatoires sont disponibles sur le site du Crédit Agricole.
The announcement of upcoming General Meetings allows investors to anticipate key decisions and potential changes in governance or strategy that could impact share value.
Rapport Therapeutics (Nasdaq: RAPP) appointed Dr. Jeffrey Sevigny as chief medical officer, effective immediately. He brings over 15 years of experience in clinical drug development in neuroscience.
The appointment of Dr. Jeffrey Sevigny as CMO signals strong leadership and expertise in drug development, potentially enhancing Rapport Therapeutics' innovation and market position in CNS disorders.
Rapport Therapeutics, Inc. (Nasdaq: RAPP) will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025, from 3:10-3:40pm EST, focusing on CNS disorder treatments.
Rapport Therapeutics presenting at investor conferences signals potential growth and interest in their developments, influencing investor sentiment and stock performance.
Rapport released new data from Phase 1 PET and MAD-2 trials for RAP-219, a potential precision medicine targeting CNS disorders.
New trial data for RAP-219 could indicate potential breakthroughs in treating CNS disorders, influencing future revenue projections and investment interest in Rapport.
Frequently Asked Questions About RAPP Stock
What is Rapport Therapeutics Inc.'s (RAPP) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Rapport Therapeutics Inc. (RAPP) has a median price target of $35.00. The highest price target is $42.00 and the lowest is $35.00.
Is RAPP stock a good investment in 2025?
According to current analyst ratings, RAPP has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $10.51. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RAPP stock?
Wall Street analysts predict RAPP stock could reach $35.00 in the next 12 months. This represents a 233.0% increase from the current price of $10.51. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Rapport Therapeutics Inc.'s business model?
Rapport Therapeutics generates revenue by developing innovative therapies aimed at treating neurological disorders. The company utilizes a unique platform that integrates neuroscience, medicinal chemistry, and genetics, allowing it to identify and create targeted drug candidates. By addressing unmet medical needs in areas like epilepsy and neuropathic pain, it positions itself to capture significant market opportunities.
What is the highest forecasted price for RAPP Rapport Therapeutics Inc.?
The highest price target for RAPP is $42.00 from Justin Walsh at Jones Trading, which represents a 299.6% increase from the current price of $10.51.
What is the lowest forecasted price for RAPP Rapport Therapeutics Inc.?
The lowest price target for RAPP is $35.00 from Andrew Tsai at Jefferies, which represents a 233.0% increase from the current price of $10.51.
What is the overall RAPP consensus from analysts for Rapport Therapeutics Inc.?
The overall analyst consensus for RAPP is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $35.00.
How accurate are RAPP stock price projections?
Stock price projections, including those for Rapport Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
